Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2018 04:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer

First-in-human Phase 1b / 2 combination trial of BXCL701 and pembrolizumab (Keytruda®) expected to initiate in 4Q 2018 Efficacy study with objective response rate endpoint to enroll up to 40 patients...
November 02, 2018 06:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Host Third Quarter 2018 Financial Results and Business Update Conference Call

Conference call scheduled for November 09, 2018 at 8:00 AM ET NEW HAVEN, Conn., Nov. 02, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage...
October 31, 2018 04:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Announces Presentation on Functional Immunological Memory Formation Across Diverse Tumor Types at the SITC 2018 Annual Meeting

Data underscores the potential of triple combination of BXCL701, NKTR-214 and an anti-PD1 agent as an anti-cancer therapy NEW HAVEN, Conn., Oct. 31, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics,...
October 30, 2018 04:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Provides Update on the Clinical Advancement of BXCL501 for the Acute Treatment of Agitation

On track to initiate BXCL501 first-in-human pharmacokinetic (bioavailability) and safety study Data readout expected first half 2019 NEW HAVEN, Conn., Oct. 30, 2018 (GLOBE NEWSWIRE) -- BioXcel...
October 11, 2018 16:01 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Present at the 2018 BIO Investor Forum

NEW HAVEN, Conn., Oct. 11, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
October 08, 2018 07:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Announces Submission of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer

NEW HAVEN, Conn., Oct. 08, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
September 24, 2018 07:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Expands Immuno-Oncology Partnership with Nektar into Clinical Development in Pancreatic Cancer

NEW HAVEN, Conn., Sept. 24, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
September 18, 2018 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Enhances Leadership with Appointment of Chetan D. Lathia, Ph.D. as Senior Vice President, and Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs

NEW HAVEN, Conn., Sept. 18, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
September 04, 2018 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Appoints Dr. David C. Hanley as Vice President and Head of Global Pharmaceutical Development and Operations

BRANFORD, Conn., Sept. 04, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
August 28, 2018 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Present at the 20th Annual HC Wainwright Global Investment Conference

NEW HAVEN, Conn., Aug. 28, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...